Tofacitinib-Loaded Nanostructured Lipid Carriers: Formulation, Characterization and In Vitro Release

References

[1] Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231–248.

[2] Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007;59(7):667–676.

[3] Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3–4):278–287.

[4] Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–420.

[5] Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442–453.

[6] Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, et al. The mechanism of action of tofacitinib, an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318–328.

[7] Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42(4):759–773.

[8] Ganesan P, Narayanasamy D. Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain Chem Pharm. 2017;6:37–56.

[9] Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: design and in vivo study. J Adv Res. 2016;7(3):423–434.

[10] Shangguan M, Lu Y, Qi J, Han J, Tian Z, Xie Y, et al. Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin. J Biomater Appl. 2014;28(6):887–896.

[11] Paudel A, Ameeduzzafar, Imam SS, Fazil M, Khan S, Hafeez A, et al. Formulation and optimization of candesartan cilexetil nano lipid carrier: in vitro and in vivo evaluation. Curr Drug Deliv. 2017;14(7):1005–1015.

[12] Fathi HA, Allam A, Elsabahy M, Fetih G, El-Badry M. Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids Surf B Biointerfaces. 2018;162:236–245.

[13] Murthy A, Ravi PR, Kathuria H, Malekar S. Oral bioavailability enhancement of raloxifene with nanostructured lipid carriers. Nanomaterials. 2020;10(6):1085.

[14] Deepika V, Naik SS. Design and development of solid lipid nanoparticles of tofacitinib citrate for the treatment of rheumatoid arthritis: a Quality by Design approach. Int J Drug Deliv Technol. 2024;14(3):1479–1486.

@article{1724979,
      author = {Bagam Bhageerath, I. Nagaraju, Dr. G. Ramesh, G. Vijaya Kumar},
      title = {Tofacitinib-Loaded Nanostructured Lipid Carriers: Formulation, Characterization and In Vitro Release},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {5},
      pages = {2033-2042},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1724979.pdf},
      abstract = {Tofacitinib is an orally administered Janus kinase inhibitor. Nanostructured lipid carriers (NLCs) combine solid and liquid lipids and may alter drug dispersion, association and release in the gastrointestinal environment. This study examined a tofacitinib-loaded NLC system.

Candidate lipids and surfactants were screened, and five batches (F1–F5) containing glyceryl monostearate (solid lipid) and oleic acid (liquid lipid) were compared. Dispersions were prepared by high-pressure homogenization and/or ultrasonication. Particle size, polydispersity index (PDI), zeta potential and entrapment efficiency were measured; compatibility and solid-state behavior were examined by FTIR, DSC and XRD. In vitro release, three-month colloidal stability and a summarized oral pharmacokinetic comparison were evaluated.

Batch F5 showed a mean particle size of 118.5 nm, PDI of 0.198, zeta potential of −32.1 mV and entrapment efficiency of 88.9%. Cumulative release at 24 h was 96.5% for F5 and 82.1% for pure drug, with the Higuchi model giving the best fit (R² = 0.987). After three months, particle size, entrapment efficiency and zeta potential changed from 118.5 to 125.2 nm, from 88.9% to 86.7% and from −32.1 to −30.4 mV, respectively. Reported Cmax values were 3.9 µg/mL (NLC) and 1.8 µg/mL (pure drug), and AUC values were 29.8 and 12.4 (units not stated).

A tofacitinib-containing NLC dispersion with favorable colloidal properties and greater in vitro release than pure drug was prepared. The pharmacokinetic difference is preliminary and requires confirmation with complete, dose-normalized data.},
      keywords = {in vitro release, nanostructured lipid carriers, oral delivery, pharmacokinetics, tofacitinib},
      month = {November},
      doi = {https://doi.org/10.64388/ire1724979}
  }